Previous Close | 6.95 |
Open | 7.02 |
Bid | 7.30 x 2200 |
Ask | 7.34 x 1400 |
Day's Range | 6.96 - 7.34 |
52 Week Range | 6.15 - 11.03 |
Volume | 1,331,246 |
Avg. Volume | 1,437,661 |
Market Cap | 530.414M |
Beta (3Y Monthly) | 2.29 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.33 |
Earnings Date | Nov 5, 2019 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 23.70 |
Biotech investment is fraught with risk. Most biotech stocks are at the mercy of binary events, which serve as make-or-break catalysts. These binary events , however, provide an opportunity for making ...
By David Bautz, PhD NASDAQ:VKTX READ THE FULL VKTX RESEARCH REPORT Business Update Phase 2b VOYAGE Trial Initiated On November 19, 2019, Viking Therapeutics, Inc. (NASDAQ:VKTX) announced that the Phase 2b VOYAGE trial of VK2809 in patients with biopsy-confirmed nonalcoholic steatohepatitis (NASH) is underway. The randomized, double blind, placebo-controlled trial is expected to enroll
SAN DIEGO, Nov. 19, 2019 /PRNewswire/ -- Viking Therapeutics, Inc. (Viking) (VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced the initiation of a Phase 2b clinical trial of VK2809, its novel liver-selective thyroid hormone receptor beta agonist, in patients with biopsy-confirmed non-alcoholic steatohepatitis (NASH). Clinical trial sites are open for patient enrollment following clearance of the company's Investigational New Drug (IND) application by the United States Food and Drug Administration (FDA).
Q3 2019 Viking Therapeutics Inc Earnings Call
SAN DIEGO , Nov. 12, 2019 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic ...
Is Viking Therapeutics, Inc. (NASDAQ:VKTX) a good place to invest some of your money right now? We can gain invaluable insight to help us answer that question by studying the investment trends of top investors, who employ world-class Ivy League graduates, who are given immense resources and industry contacts to put their financial expertise to […]
By David Bautz, PhD NASDAQ:VKTX READ THE FULL VKTX RESEARCH REPORT Business Update IND Filed for VK2809; P2b Trial to Initiate in 4Q19 On November 5, 2019, Viking Therapeutics, Inc. (NASDAQ:VKTX) provided a business update, which included the announcement that the Investigational New Drug (IND) application for VK2809 has been submitted to the FDA such that a Phase 2b clinical trial in patients
Dow Jones closes at a new record high of 27,492.63 Continue reading...
Conference call scheduled for 8:30 a.m. ET today - IND Application Filed for Phase 2b Study of VK2809 in Biopsy-Confirmed NASH - Clinical Development of VK0214 for X-ALD Expected to Begin 1H20 - Balance ...
Conference Call Scheduled for Tuesday, November 5 at 8:30 a.m. Eastern Time SAN DIEGO , Oct. 31, 2019 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical ...
SAN DIEGO , Sept. 25, 2019 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic ...
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
The biotech rivals each aim to dominate the treatment market for non-alcoholic steatohepatitis (NASH).
These small-cap stocks hold the potential to deliver big-time returns.
What you need to know about this high-risk, high-reward biotech stock.
Q2 2019 Viking Therapeutics Inc Earnings Call
VKTX earnings call for the period ending June 30, 2019.
It's one of the more promising companies in the race to develop a successful NASH treatment. Will patient investors be rewarded?
Viking Therapeutics, Inc. (VKTX) is currently preparing for the initiation of a Phase 2b clinical trial of VK2809, the company’s thyroid beta receptor (TRβ) agonist, for the treatment of nonalcoholic steatohepatitis (NASH). The company has submitted a pre-IND briefing package to the FDA and is currently awaiting written feedback.
Conference call scheduled for 4:30 p.m. ET today - Preparation for Phase 2b Study of VK2809 in Biopsy-Confirmed NASH Underway; Expect to Commence Enrollment in 2H19 - Continued Progress with VK0214 for ...
Spread activity is detected today in VKTX's options pits
Conference Call Scheduled for Thursday, August 1 at 4:30 p.m. Eastern Time SAN DIEGO , July 25, 2019 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical ...
Is Viking Therapeutics, Inc. (NASDAQ:VKTX) a good place to invest some of your money right now? We can gain invaluable insight to help us answer that question by studying the investment trends of top investors, who employ world-class Ivy League graduates, who are given immense resources and industry contacts to put their financial expertise to […]
Viking Therapeutics (VKTX) stock closed at $7.98 on June 12, 2.70% higher than its previous close, 14.49% above its 52-week low of $6.97, and 66.75% below its 52-week high of $24.